CP
CRL icon

Camelot Portfolios’s Charles River Laboratories CRL Stock Holding History

Camelot Portfolios’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-5,941
Closed -$908K – 215
2019
Q4 		$908K Buy
+5,941
New +$823K 0.38% 70

Other funds holding CRL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
EIP
Epoch Investment Partners New York $16.5B AUM 24.3% 1-Year Est. Return

Camelot Portfolios's CRL Position: Q1 2020 in Review

Camelot Portfolios sold out of Charles River Laboratories (CRL) in Q1 2020, closing a stake of 5,941 shares — an estimated $908K sold.

Camelot Portfolios first reported a position in CRL in Q4 2019 and held it in 1 quarter. The position peaked at $908K in Q4 2019. 416 funds tracked by Wall St. Rank hold CRL as of Q1 2020.

  • Camelot Portfolios reported no remaining Charles River Laboratories position as of Q1 2020 after selling out during the quarter.
  • Camelot Portfolios sold 5,941 Charles River Laboratories shares in Q1 2020, an estimated $908K.
  • Camelot Portfolios first reported a position in Charles River Laboratories in Q4 2019 and held it in 1 quarter.
  • Camelot Portfolios's Charles River Laboratories position peaked at $908K in Q4 2019.
  • 416 funds tracked by Wall St. Rank held Charles River Laboratories as of Q1 2020.

Based on Camelot Portfolios's 13F filing for Q1 2020, filed 28 Apr 2020.